10 year course of IQ in first-episode psychosis: Relationship between duration of psychosis and long-term intellectual trajectories

Psychiatry Research

Volumn 225, Issue 3, 2015, Pages 515-521

  Barder, Helene Eidsmo ^a,b   Sundet, Kjetil ^a,b   Rund, Bjørn Rishovd ^b,c   Evensen, Julie ^a,b   Haahr, Ulrik ^e   ten Velden Hegelstad, Wenche ^f   Joa, Inge ^f,g   Johannessen, Jan Olav ^f,g   Langeveld, Johannes ^f   Larsen, Tor Ketil ^f,h   Melle, Ingrid ^a,b   Opjordsmoen, Stein ^a,b   Røssberg, Jan Ivar ^a,b   Simonsen, Erik ^d   Vaglum, Per ^b   McGlashan, Thomas ⁱ   Friis, Svein ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Psychiatric Research Unit   (Denmark)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF STAVANGER   (Norway)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Longitudinal; Neurocognition; Positive symptoms; Psychosis; Subgroups; WAIS R

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; CORE SCHIZOPHRENIA SPECTRUM DISORDER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DURATION OF PSYCHOSIS AFTER START OF TREATMENT; DURATION OF UNTREATED PSYCHOSIS; FEMALE; FOLLOW UP; HUMAN; IMMEDIATE VERBAL RECALL; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON CORE SCHIZOPHRENIA SPECTRUM DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PREMORBID ADJUSTMENT SCALE; PSYCHOSIS; RECALL; TIME SERIES ANALYSIS; WECHSLER INTELLIGENCE SCALE; WORKING MEMORY; ADOLESCENT; COGNITION DISORDERS; COMORBIDITY; INTELLIGENCE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; ADULT; COGNITION DISORDERS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTELLIGENCE; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84922933711     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.11.054     Document Type: Article

References (47)

1. Barder H.E., Sundet K., Rund B.R., Evensen J., Haahr U., Ten Velden Hegelstad W., Joa I., Johannessen J.O., Langeveld H., Larsen T.K., Melle I., Opjordsmoen S., Rossberg J.I., Simonsen E., Vaglum P., McGlashan T., Friis S. Neurocognitive development in first episode psychosis 5 years follow-up: associations between illness severity and cognitive course. Schizophrenia Research 2013, 149(1-3):63-69. 10.1016/j.schres.2013.06.016.
2. Barder H.E., Sundet K., Rund B.R., Evensen J., Haahr U., Ten Velden Hegelstad W., Joa I., Johannessen J.O., Langeveld J., Larsen T.K., Melle I., Opjordsmoen S., Rossberg J.I., Simonsen E., Vaglum P., McGlashan T., Friis S. Ten year neurocognitive trajectories in first-episode psychosis. Frontiers in Human Neuroscience 2013, 7:643. 10.3389/fnhum.2013.00643.
3. Barnett J.H., Salmond C.H., Jones P.B., Sahakian B.J. Cognitive reserve in neuropsychiatry. Psychological Medicine 2006, 36(8):1053-1064. 10.1017/S0033291706007501.
4. Becker H.E., Nieman D.H., Wiltink S., Dingemans P.M., van de Fliert J.R., Velthorst E., de Haan L., van Amelsvoort T.A., Linszen D.H. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?. Psychological Medicine 2010, 40(10):1599-1606. 10.1017/S0033291710000048.
5. Bora E., Murray R.M. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophrenia Bulletin 2013, 40(4):744-755. 10.1093/schbul/sbt085.
6. Braw Y., Bloch Y., Mendelovich S., Ratzoni G., Gal G., Harari H., Tripto A., Levkovitz Y. Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophrenia Bulletin 2008, 34(3):544-554. 10.1093/schbul/sbm115.
7. Brissos S., Dias V.V., Balanza-Martinez V., Carita A.I., Figueira M.L. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophrenia Research 2011, 129(2-3):133-136. 10.1016/j.schres.2011.04.001.
8. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 1982, 8(3):470-484. 10.1093/schbul/8.3.470.
9. Collin G., Derks E.M., van Haren N.E., Schnack H.G., Hulshoff Pol H.E., Kahn R.S., Cahn W. Symptom dimensions are associated with progressive brain volume changes in schizophrenia. Schizophrenia Research 2012, 138(2-3):171-176. 10.1016/j.schres.2012.03.036.
10. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990, 16(1):57-67. 10.1093/schbul/16.1.57.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P) 1995, New York State Psychiatric Institute, Biometrics Research, New York, (version 2).
12. Friis S., Sundet K., Rund B.R., Vaglum P., McGlashan T.H. Neurocognitive dimensions characterising patients with first-episode psychosis. British Journal of Psychiatry Supplement 2002, 43:S85-S90. 10.1192/bjp.181.43.s85.
13. Frommann I., Pukrop R., Brinkmeyer J., Bechdolf A., Ruhrmann S., Berning J., Decker P., Riedel M., Moller H.J., Wolwer W., Gaebel W., Klosterkotter J., Maier W., Wagner M. Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early-and additional memory dysfunction in the late-prodromal state. Schizophrenia Bulletin 2011, 37(4):861-873. 10.1093/schbul/sbp155.
14. Fusar-Poli P., Deste G., Smieskova R., Barlati S., Yung A.R., Howes O., Stieglitz R.D., Vita A., McGuire P., Borgwardt S. Cognitive functioning in prodromal psychosis: a meta-analysis. Archives of General Psychiatry 2012, 69(6):562-571. 10.1001/archgenpsychiatry.2011.1592.
15. Giuliano A.J., Li H., Mesholam-Gately R.I., Sorenson S.M., Woodberry K.A., Seidman L.J. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Current Pharmaceutical Design 2012, 18(4):399-415. 10.2174/138161212799316019.
16. Gold S., Arndt S., Nopoulos P., O'Leary D.S., Andreasen N.C. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. American Journal of Psychiatry 1999, 156(9):1342-1348. (doi: http://www.ncbi.nlm.nih.gov/pubmed/10484943).
17. Hallmayer J.F., Kalaydjieva L., Badcock J., Dragovic M., Howell S., Michie P.T., Rock D., Vile D., Williams R., Corder E.H., Hollingsworth K., Jablensky A. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. American Journal of Human Genetics 2005, 77(3):468-476. 10.1086/432816.
18. Hedman A.M., van Haren N.E., van Baal C.G., Kahn R.S., Hulshoff Pol H.E. IQ change over time in schizophrenia and healthy individuals: a meta-analysis. Schizophrenia Research 2013, 146(1-3):201-208. 10.1016/j.schres.2013.01.027.
19. Heinrichs R.W. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 2007, 64(6):631-632. 10.1001/archpsyc.64.6.631.
20. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445. 10.1037//0894-4105.12.3.426.
21. Ho B.C., Alicata D., Ward J., Moser D.J., O'Leary D.S., Arndt S., Andreasen N.C. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. American Journal of Psychiatry 2003, 160(1):142-148. 10.1176/appi.ajp.160.1.142.
22. Kahn R.S., Keefe R.S. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013, 70(10):1107-1112. 10.1001/jamapsychiatry.2013.155.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276. 10.1093/schbul/13.2.261.
24. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 2007, 64(6):633-647. CATIE Investigators, Neurocognitive Working GroupNeurocognitive Working Group. 10.1001/archpsyc.64.6.633.
25. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Rock S.L., Woolson S., Tohen M., Tollefson G.D., Sanger T.M., Lieberman J.A., Group H.R. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry 2006, 59(2):97-105. 10.1016/j.biopsych.2005.06.022.
26. Kremen W.S., Seidman L.J., Faraone S.V., Toomey R., Tsuang M.T. Heterogeneity of schizophrenia: a study of individual neuropsychological profiles. Schizophrenia Research 2004, 71(2-3):307-321. 10.1016/j.schres.2004.02.022.
27. Kurtz M.M. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophrenia Research 2005, 74(1):15-26. 10.1016/j.schres.2004.07.005.
28. Larsen T.K., Friis S., Haahr U., Johannessen J.O., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P.V., McGlashan T.H. Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. British Journal of Psychiatry 2004, 185:108-115. 10.1192/bjp.185.2.108.
29. Lezak M.D., Howieson D.B., Looring D.W. Neuropsychological Assessment 2004, Oxford University Press, New York.
30. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Journal of Clinical Psychiatry 1996, 57(Suppl. 9):S5-S9. (doi: http://www.ncbi.nlm.nih.gov/pubmed/8823344).
31. Meier M.H., Caspi A., Reichenberg A., Keefe R.S., Fisher H.L., Harrington H., Houts R., Poulton R., Moffitt T.E. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. American Journal of Psychiatry 2013, 171(1):91-101. 10.1176/appi.ajp.2013.12111438.
32. Melle I., Larsen T.K., Haahr U., Friis S., Johannessen J.O., Opjordsmoen S., Simonsen E., Rund B.R., Vaglum P., McGlashan T. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Archives of General Psychiatry 2004, 61(2):143-150. 10.1001/archpsyc.61.2.143.
33. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23(3):315-336. 10.1037/a0014708.
34. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 2004, 72(1):29-39. 10.1016/j.schres.2004.09.007.
35. Nuechterlein K.H., Subotnik K.L., Green M.F., Ventura J., Asarnow R.F., Gitlin M.J., Yee C.M., Gretchen-Doorly D., Mintz J. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophrenia Bulletin 2011, 37(Suppl. 2):S33-S40. 10.1093/schbul/sbr084.
36. Rund B.R. Does active psychosis cause neurobiological pathology? A critical review of the neurotoxicity hypothesis. Psychological Medicine 2014, 40(8):1577-1590. 10.1017/S0033291713002341.
37. Rund B.R., Melle I., Friis S., Johannessen J.O., Larsen T.K., Midboe L.J., Opjordsmoen S., Simonsen E., Vaglum P., McGlashan T. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophrenia Research 2007, 91(1-3):132-140. 10.1016/j.schres.2006.11.030.
38. Rund B.R., Melle I., Friis S., Larsen T.K., Midboe L.J., Opjordsmoen S., Simonsen E., Vaglum P., McGlashan T. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. American Journal of Psychiatry 2004, 161(3):466-472. 10.1176/appi.ajp.161.3.466.
39. Simonsen C., Sundet K., Vaskinn A., Birkenaes A.B., Engh J.A., Faerden A., Jonsdottir H., Ringen P.A., Opjordsmoen S., Melle I., Friis S., Andreassen O.A. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophrenia Bulletin 2011, 37(1):73-83. 10.1093/schbul/sbp034.
40. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. Journal of the International Neuropsychological Society 2002, 8(3):448-460. (doi: http://www.ncbi.nlm.nih.gov/pubmed/11939702).
41. Tamminga C.A., Buchanan R.W., Gold J.M. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. International Clinical Psychopharmacology 1998, 13(Suppl. 3):S21-S26. 10.1097/00004850-199803003-00004.
42. Ventura J., Thames A.D., Wood R.C., Guzik L.H., Hellemann G.S. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophrenia Research 2010, 121(1-3):1-14. 10.1016/j.schres.2010.05.033.
43. Walters J.T., Corvin A., Owen M.J., Williams H., Dragovic M., Quinn E.M., Judge R., Smith D.J., Norton N., Giegling I., Hartmann A.M., Moller H.J., Muglia P., Moskvina V., Dwyer S., O'Donoghue T., Morar B., Cooper M., Chandler D., Jablensky A., Gill M., Kaladjieva L., Morris D.W., O'Donovan M.C., Rujescu D., Donohoe G. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Archives of General Psychiatry 2010, 67(7):692-700. 10.1001/archgenpsychiatry.2010.81.
44. Wechsler D. Wechsler Adult Intelligence Scale-Revised 1981, New York Psychological Corp, New York.
45. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: a meta-analytic review. American Journal of Psychiatry 2008, 165(5):579-587. 10.1176/appi.ajp.2008.07081242.
46. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 2005, 8(3):457-472. 10.1017/S146114570500516X.
47. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 1991, 17(2):325-351. 10.1093/schbul/17.2.325.